Translations:Insulin analog/8/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 17:49, 19 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Insulin analog)
===Degludec insulin===
{{main|Insulin degludec}}
This is an ultralong-acting insulin analogue developed by [[Novo Nordisk]], which markets it under the brand name Tresiba. It is administered once daily and has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir).

Degludec insulin

Main article: Insulin degludec

This is an ultralong-acting insulin analogue developed by Novo Nordisk, which markets it under the brand name Tresiba. It is administered once daily and has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir).

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Insulin_analog/8/en&oldid=130144"